1 – 10 of 10
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Large differencies in age-specific survival in multiple myeloma in the nordic countries
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Deciphering the genetics and mechanisms of predisposition to multiple myeloma
(
- Contribution to journal › Article
- 2022
-
Mark
Outcome data from >10 000 multiple myeloma patients in the Danish and Swedish national registries
(
- Contribution to journal › Article
-
Mark
Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma : A randomised phase 2 trial by the Nordic Myeloma Study Group
(
- Contribution to journal › Article
- 2021
-
Mark
Germline variants at SOHLH2 influence multiple myeloma risk
(
- Contribution to journal › Article
- 2018
-
Mark
Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma
(
- Contribution to journal › Article
- 2016
-
Mark
Genome-wide association study identifies multiple susceptibility loci for multiple myeloma
(
- Contribution to journal › Article
- 2015
-
Mark
Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma.
(
- Contribution to journal › Article
- 2012
-
Mark
Impact of polymorphic variation at 7p15.3, 3p22.1 and 2p23.3 loci on risk of multiple myeloma
(
- Contribution to journal › Letter
- 2010
-
Mark
Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial
(
- Contribution to journal › Article